History of other malignancy that could affect compliance with the protocol or interpretation of results
Any medical condition or laboratory test abnormality that precludes the participant's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results
History of other malignancy that could affect compliance with the protocol or interpretation of results
Evidence of any significant, uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results
History of other malignancy that could affect compliance with the protocol or interpretation of results
Have a second primary malignancy that in the judgment of the investigator or Lilly may affect the interpretation of results.
Have known acute or chronic leukemia or current hematologic malignancies (except iNHL for patients in Part B5) that, in the judgment of the investigator and sponsor, may affect the interpretation of results
Have a second primary malignancy that in the judgment of the investigator and sponsor may affect the interpretation of results (Part B only)
History of other malignancy that could affect compliance with the protocol or interpretation of results
A second primary malignancy that in the judgment of the principal investigator (PI) or designee may affect the interpretation of results
History of other malignancy that could affect compliance with the protocol or interpretation of results
History of other malignancy that could affect compliance with the protocol or interpretation of results
History of other malignancy, autoimmune disease, or any significant, uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results
History of other malignancy that could affect compliance with the protocol or interpretation of results
History of other malignancy that could affect compliance with the protocol or interpretation of results
History of other malignancy, which could affect compliance with the protocol or interpretation of results
Second primary malignancy that may affect the interpretation of results
Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results
History of other malignancy that could affect compliance with the protocol or interpretation of results
Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results
Have a second primary malignancy that in the judgment of the investigator and Medical Monitor may affect the interpretation of results.
Have known acute or chronic leukemia or current hematologic malignancies that, in the judgment of the investigator and sponsor, may affect the interpretation of results.
Have a second primary malignancy that in the judgment of the investigator and medical monitor may affect the interpretation of results.
Have a second primary malignancy that, in the judgment of the investigator and sponsor, may affect the interpretation of results.
Have a second primary malignancy that, in the judgment of the investigator and sponsor, may affect the interpretation of results. Curatively treated nonmelanoma skin cancer or in situ carcinoma of any origin is allowed.
History of other malignancy that could affect compliance with the protocol or interpretation of results
Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results or that could increase risk to the participant
-  Evidence of any significant disease or condition that could affect compliance with the protocol or interpretation of results.
Have second primary malignancy that may affect the interpretation of results.
Have a second primary malignancy that in the judgment of the investigator and sponsor may affect the interpretation of results
Patients with a second malignancy that might interfere with interpretation of the results of this study
Significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results
